Organization (Industry)
NOVALIQ GmbH
ClinicalTrials.gov lists NOVALIQ GmbH as lead sponsor of 13 trials. It has 3 active development programs and 3 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers NOVALIQ GmbH: 13 lead-sponsored trials and 2 legal-entity registrations.
Disease areas (1)
| Disease area | Trials |
|---|---|
| Dry Eye Syndromes | 11 |
Trials by start year as sponsor or collaborator (10)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2024 | 1 |
| 2021 | 1 |
| 2020 | 2 |
| 2018 | 1 |
| 2017 | 1 |
| 2016 | 2 |
| 2015 | 2 |
| 2014 | 1 |
| 2013 | 1 |
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (3)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Vehicle topical ocular, eye drops | Dry Eye Syndromes | Phase 3 | 2 |
| CyclASol topical ocular, eye drops | Dry Eye Syndromes | Phase 3 | 2 |
| CyclASol Ophthalmic Solution | Dry Eye Syndromes | Phase 3 | 1 |
Approved assets (3)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Cyclosporine ophthalmic solution 0.1% | 1 |
| MIEBO™ (Perfluorohexyloctane, PFHO) | 1 |
| CYCLOSPORINE | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 100% hit target (n=5) | 83% on time (n=6) |
Journals published in (5)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Cornea | 3 |
| Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics | 2 |
| JAMA ophthalmology | 1 |
| Journal of cataract and refractive surgery | 1 |
| Ophthalmology | 1 |
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 50 | 24 | 2025-12-16 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 3 | 2026-05-06 |
Latest dated events (66)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-05-06 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-03-16 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-16 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-12-09 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2025-11-21 | FDA import refusal | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
Showing 5 of 66 events.
Biomarker capability evidence (15)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AATF | Trial sponsor | Named in trial inclusion criteria |
| AATF | Trial sponsor | Named in trial inclusion criteria |
| AATF | Trial sponsor | Named in trial inclusion criteria |
| AATF | Trial sponsor | Named in trial inclusion criteria |
| AATF | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 15 evidence rows.
On Scientist.com
NOVALIQ GmbH is listed as a research supplier in the Scientist.com network.
Novaliq GmbH is a drug delivery company located in the Heidelberg Technology Park, Germany. They develop innovative pharmaceutical formulations based on semifluorinated alkanes (SFAs). Their patented SFAs can be used in various routes of administration for the transport of drugs or oxygen for therapeutic purposes. Novaliq currently develops novel ophthalmic and dermatological products as well as solutions for organ preservation, based on the unique physicochemical properties of SFA. Their first and preservative free eye drop product (OTC) is NovaTears® for the relief of discomfort under dry...
Show the full description
Novaliq GmbH is a drug delivery company located in the Heidelberg Technology Park, Germany. They develop innovative pharmaceutical formulations based on semifluorinated alkanes (SFAs).
Their patented SFAs can be used in various routes of administration for the transport of drugs or oxygen for therapeutic purposes. Novaliq currently develops novel ophthalmic and dermatological products as well as solutions for organ preservation, based on the unique physicochemical properties of SFA.
Their first and preservative free eye drop product (OTC) is NovaTears® for the relief of discomfort under dry eye syndrome. The product is available in standard multi dose units.
Besides the development of its own products and licensing them to pharmaceutical distributors, Novaliq is offering its SFA technology as a delivery platform for external co-development cooperations.
- Website
- novaliq.de
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.
Work with Novaliq GmbH on Scientist.com
For prices, more details, or to contact Novaliq GmbH, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.